These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 25481455)

  • 1. Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis.
    Sommariva S; Tarricone R; Lazzeri M; Ricciardi W; Montorsi F
    Eur Urol; 2016 Jan; 69(1):107-15. PubMed ID: 25481455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy.
    Freedland SJ; Gerber L; Reid J; Welbourn W; Tikishvili E; Park J; Younus A; Gutin A; Sangale Z; Lanchbury JS; Salama JK; Stone S
    Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):848-53. PubMed ID: 23755923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell cycle progression score improves risk stratification in prostate cancer patients with adverse pathology after radical prostatectomy.
    Shangguan X; Qian H; Jiang Z; Xin Z; Pan J; Dong B; Xue W
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):687-694. PubMed ID: 31745702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.
    Cooperberg MR; Simko JP; Cowan JE; Reid JE; Djalilvand A; Bhatnagar S; Gutin A; Lanchbury JS; Swanson GP; Stone S; Carroll PR
    J Clin Oncol; 2013 Apr; 31(11):1428-34. PubMed ID: 23460710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.
    Cuzick J; Swanson GP; Fisher G; Brothman AR; Berney DM; Reid JE; Mesher D; Speights VO; Stankiewicz E; Foster CS; Møller H; Scardino P; Warren JD; Park J; Younus A; Flake DD; Wagner S; Gutin A; Lanchbury JS; Stone S;
    Lancet Oncol; 2011 Mar; 12(3):245-55. PubMed ID: 21310658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
    Arsov C; Jankowiak F; Hiester A; Rabenalt R; Quentin M; Schimmöller L; Blondin D; Antoch G; Albers P
    Anticancer Res; 2014 May; 34(5):2459-66. PubMed ID: 24778061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell cycle progression score and treatment decisions in prostate cancer: results from an ongoing registry.
    Crawford ED; Scholz MC; Kar AJ; Fegan JE; Haregewoin A; Kaldate RR; Brawer MK
    Curr Med Res Opin; 2014 Jun; 30(6):1025-31. PubMed ID: 24576172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence.
    Koch MO; Cho JS; Kaimakliotis HZ; Cheng L; Sangale Z; Brawer M; Welbourn W; Reid J; Stone S
    Cancer Biomark; 2016 Jun; 17(1):83-8. PubMed ID: 27314296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer.
    Canter DJ; Reid J; Latsis M; Variano M; Halat S; Rajamani S; Gurtner KE; Sangale Z; Brawer M; Stone S; Bardot S
    Eur Urol; 2019 Mar; 75(3):515-522. PubMed ID: 30391079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does the extent of carcinoma in prostatic biopsies predict prostate-specific antigen recurrence? A systematic review.
    Harnden P; Shelley MD; Naylor B; Coles B; Mason MD
    Eur Urol; 2008 Oct; 54(4):728-39. PubMed ID: 18603352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy.
    Canter DJ; Freedland S; Rajamani S; Latsis M; Variano M; Halat S; Tward J; Cohen T; Stone S; Schlomm T; Bishoff J; Bardot S
    Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):102-107. PubMed ID: 31243337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-cycle Progression-score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients.
    Oderda M; Cozzi G; Daniele L; Sapino A; Munegato S; Renne G; De Cobelli O; Gontero P
    Urology; 2017 Apr; 102():73-78. PubMed ID: 27894974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2017; 17(6):1-75. PubMed ID: 28572867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of a cell cycle progression score for men with prostate cancer.
    Cuzick J
    Recent Results Cancer Res; 2014; 202():133-40. PubMed ID: 24531787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.
    Chade DC; Eastham J; Graefen M; Hu JC; Karnes RJ; Klotz L; Montorsi F; van Poppel H; Scardino PT; Shariat SF
    Eur Urol; 2012 May; 61(5):961-71. PubMed ID: 22280856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review.
    van den Bergh RC; van Casteren NJ; van den Broeck T; Fordyce ER; Gietzmann WK; Stewart F; MacLennan S; Dabestani S; Bellmunt J; Bolla M; Briers E; Cornford P; Joniau S; Mason MD; Matveev V; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Lam TB; Mottet N
    Eur Urol; 2016 May; 69(5):802-20. PubMed ID: 26691493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort.
    Cuzick J; Stone S; Fisher G; Yang ZH; North BV; Berney DM; Beltran L; Greenberg D; Møller H; Reid JE; Gutin A; Lanchbury JS; Brawer M; Scardino P
    Br J Cancer; 2015 Jul; 113(3):382-9. PubMed ID: 26103570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual estimation of tumour extent is not an independent predictor of prostate specific antigen recurrence.
    Jones TD; Koch MO; Lin H; Cheng L
    BJU Int; 2005 Dec; 96(9):1253-7. PubMed ID: 16287440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.